According to the Cancer Genome Atlas database, the most frequent somatic mutations in RCC mainly include changes in the VHL gene, followed by alterations of the PI(3)K/AKT/mTOR pathway, thus affecting the response of the patient to the therapy [7,8,10]. This evidence concerns the gene MTOR and renal cell carcinoma.